3 April 2018 - Duration-7 study results showed significant HbA1c reduction when Bydureon was added to insulin glargine therapy vs insulin glargine alone.

AstraZeneca today announced the US FDA has approved Bydureon (exenatide extended-release) for injectable suspension as an add-on therapy to basal insulin in adults with type 2 diabetes with inadequate glycemic control. Bydureon is approved for adults with type 2 diabetes whose blood sugar remains uncontrolled on one or more anti-diabetic medicines in addition to diet and exercise, to improve glycemic control.

The expanded use is based on results from the 28-week DURATION-7 study, which examined the effect of Bydureon or placebo as add-on therapy to insulin glargine, with or without metformin, in adults with type 2 diabetes mellitus.

Read AstraZeneca press release